Changes in LGALS1 expression trigger changes in MDR1 expression and resistance to cytotoxic drugs, and MDR1 shows high efficacy in the treatment of BCR-ABL-positive CML, so LGALS1 may be considered as a novel target for combination therapy, used to improve the efficacy of imatinib in the treatment of CML [18]. This evidence concerns the gene LGALS1 and chronic myelogenous leukemia, BCR-ABL1 positive.